Member Info for dgaser

On 13 December 2021, Oxford Biomedica announced that Novartis extended the terms of its initial commercial supply agreement to the end of 2028 and Oxford Biomedica regained the rights to its LentiVector® platform relating to three CAR-T targets, including CD19 targeted therapies. As result of the agreement Oxford Biomedica has the right to work with potential pharmaceutical and biotech partners other than Novartis across all CAR-T targets. In addition, under the terms of the new agreement Novartis has been granted additional flexibility in ordering of GMP batches across Oxford Biomedica's multiple GMP facilities but will no longer have a minimum order commitment;

On reading the up date I notice

OXB have now up dated the market see below

www.lse.co.uk/rns/OXB/us-agreement-and-proposed-placing-of-shares-ymbfn1ztsoepfso.html

I would still prefer a take over from another company at this price .
BE HAPPY
Dave

OXB have just updated it's web site . personally I would prefer a take over offer right now ,see web site below
www.lse.co.uk/rns/OXB/us-agreement-and-proposed-placing-of-shares-ymbfn1ztsoepfso.html
BE HAPPY
DAVE

I have been trying to get an angel on why the OXB price has collapsed .The last time this fell 50%, was when our founders wife sold her shares and Sanofi handed back Trovax .

Any way I have found out a bit more about the joint venture between Oxford Bio solutions, and the American company Homology, primarily they want to set up new manufacturing /lab facilities in the US ,see web sit page below
www.oxb.com/OxfordBiomedicaandHomologyMedicines

As we know our AZ contract was for 3 years from Nov 2020,which means it is now running down ,the Novartis contact which has been extended is also running down over the next 3 years ,and with no evidence of any of our lead drugs coming to market over the next 3 years, things don't look good for OXB from the end of 2023 ,and with Sanofi handing back our eye products ,OXB income streams after 2023 don't look good.

Therefore, maybe this joint venture is their answer to that gap ,but why would our C.E.O not want to over see this venture ?

As we all ready know Novartis are also building a new big manufacturing site in the USA, for their Bio Meds, as they want to bring all their Bio product production under one roof in the state's .

To me OXB should be telling us more about this JV and the price they expect to get, as the document I have seen talks of £130m and £80m.To be honest, I would have preferred a take over of OXB ,I suppose it is possible that A.Z or one of the other big boys could step in ,and offer £10 +per share, if they did, I would snap their hand off
BE HAPPY
Dave

for

John Dawson to retire from Oxford Biomedica
Oxford, UK – 17 January 2022: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group” or “the Company”) a leading gene and cell therapy company, today announces that, after more than 13 years of service, John Dawson, Chief Executive Officer, has signalled to the Board his intention to retire from the Company. Accordingly, the Board has initiated a formal search for a successor.
Be Happy
Dave
I

t
Thats true but the market take's time to evaluate the price ,and then move/s the price once the anylists have spoken, hence you get a gap between the release of the new advice and price moven. if you have ?a better theriey for the movement north,then please advice
thanks and

be happy
Dave ,

.

As we all know saruim the Indian vaccine company purchased £50million see statement below .Obviously this will dilute the price,but should settle now ,and if every things goe's according to the agreement then the price should once again head north
Be Happy
Dave
SLS to subscribe for 3,382,950 new ordinary shares of 50 pence each in Oxford Biomedica (the "Subscription Shares") at a price oUnder the Subscription Agreement entered into by SLS and Oxford Biomedica in relation to the Transaction, f £14.78 per share, amounting to an investment of £50,000,001 (gross).



The Subscription Shares are to be issued on a non pre-emptive basis utilising the authority granted at the Group's 2021 AGM which allows Oxford Biomedica to issue ordinary shares free of pre-emption rights for the purposes of an acquisition or specified capital investment. Applications will be made for the Subscription Shares to be admitted to the premium listing segment of the Official List of the Financial Conduct Authority and to be admitted to trading on the main market for listed securities of the London Stock Exchange plc (together, "Admission"). Admission of the Subscription Shares and completion of the Transaction is expected to take place at 8.00 a.m. on 27 September 2021.

Mafuta obviously we all know Sar are involved in more than one product , but what happens on the open market will affect SAR price, especially if it affects the only product SAR have that could produce an income for them in the near future, if they could get emergency clearance. At the moment SAR have no income to cover costs , so any thing that could hinder that would also affect their price. As the company say them selfs , they have appointed consultants to advise on the design of clinical trials, and the filing is now targeted for mid-2022 ,this is to allow them to complete the necessary work. The CTA approval is seen as a key step to allowing first human studies with SDC-1801 to begin subject to drug product supply and additional funding .Sar have also said they receive grant funding from the UK government to investigate SDC-1801 as a potential treatment for the severe respiratory symptoms of Covid-19. they have since completed the research programme and generated encouraging preliminary results.
The results from the infected lung cells and in vivo disease models demonstrate that SDC-1801 reduces levels of key inflammatory agents known to play a role in the serious and potentially life-threatening hyper-inflammatory response that affects some Covid-19 patients.. S.A.R are also looking at the UK government's AGILE clinical trial platform, or other equivalent programmes, but this will take time and funding to support any Phase 1 trials with SDC-1801 for Covid-19 and hopefully they can fast-track its development, but according to their web site, any clinical trials will be determined following consultations with experts in the field. and this is what I was saying , it's possible we will still need the new therapies to treat severe respiratory inflammation arising from other viral infections despite the success of the vaccination programme for Covid19 around the world. but any thing that might hamper this program, such as the new Astra Zeneca product just announced today ,and the announcement, of the Pfizer and GSK products will make the market react negatively .
BE HAPPY DAVE

It appears ,that both Pfizer and GSK have developed new drugs for Covid 19 ,that can be taken after some one has all ready contracted covid 19, and both drugs are taken orally
The new Pfizer drug is all ready being looked at by the FDA ,UK ,and European authorities for emergency approval, and the GSK drug will be following soon after ,both drugs work well with up to 89% effectiveness .
It appears the market believes, that our product will miss the boat by the time it gets Emergency clearance after extensive trials. I also note, that other Bio's that have similar products in trials have also dipped , even Vaccine manufacturing companies' such as OXB, are heading south, OXB has fallen by over £1.50 per share. from a high of £16.00 since the announcement .
Just a thought as to why this drop is happening.
BE HAPPY
DAVE .

Hi Sorry Every one for the typo's in my first post here ,it should have read as follows .
Can I ask If CNE have done any thing in the states yet regarding the Indian problem ,I did read some time ago that CNE had been able to get £20m of assets in Europe, and were now going after Air India's headquarters in New York, and Europe, which combined are worth about 50% of what India owes us .
As to the other problem Egypt ,to me any tie ups with companies in the middle east or the Indian sub continent are risky right now, especially as many countries in this area are struggling to find the cash to immunise their own people, and they are known ,to find many other ways to raise cash ,by back dating Taxes' or levies' as India did , so any tie up with another middle eastern, or Indian country, such as Egypt ,would in my mind be a gamble ,as they say, once bitten .

Obviously counties such as Saudi, Bahrain, UAE, Kuwait etc, or other oil rich or natural gas rich countries, would obviously make more reliable partners in the long run .

like many others here ,I to, am building big losses, and like many others, I to, would welcome more news from CNE regarding the India problem .

This stock also reminds me of the saying ,don't catch a falling knife as it could hurt you, so Like many others, I will hold for the time being ,as I believe we haven't hit the bottom yet .
Unfortunately any profits CNE do make over the next few months will probably be eaten up with legal costs.
BE HAPPY
DAVE .

Hi Every one .Can I ask If CNE have done any thing in the states yet regarding the Indian problem ,I did read some time ago that CNE had been able to get £20m of assets in Europe, and where now going after Air India's headquarters in New your, and in Europe which combined is worth about 50% of what India owes us .
To me any tie ups with companies in the middle east or the Indian sub continent will be risky right now ,especially as many countries in this area are struggling to find cash to immunise their own people, and are known to find many others ways to raise cash such as Tax so any tie up with another middle eastern, or Indian countries country , such as Egypt ,would in my mind be a gamble .as they say once bitten .Obviously counties such as Saudi, Bahrain, UAE, Kuwait etc or other oil rich or natural gas rich countries would obviously make more reliable partners than Egypt in the long run .
like many others here I'm now building losses, and like many others I to would welcome more news from CNE regarding the India problem . this stock reminds me of the saying ,don't catch a falling knife as it could hurt you .
Like others I will hold for now ,as I believe we have not hit the bottom yet . and any profits here unfortunately will be eaten up with legal costs.
BE HAPPY
DAVE .

This morning an article written by both UK & Swiss scientists in the journal , caught my eye ,according to this article scientists say the A.Z jab gives powerful protection, that will last for years or even a life time .The vaccine apparently creates training camps in the body for search and destroy T cells ,this means the body can continue making the T cells long after the original antibodies have stopped working .The Researchers also said T Cell protection is a key feature of the adenovirus vaccines, developed by oxford BIO and is now manufactured by Oxford Bio at their Oxford manufacturing facilities .
This is good news for those who received the A Z jab
BE HAPPY
DAVE

This morning an article written by both UK & Swiss scientists in the journal , caught my eye ,according to this article scientists say the A.Z jab gives powerful protection, that will last for years even a life time .The vaccine apparently creates training camps in the body for search and destroy T cells ,this means the body can continue making the T cells long after the original antibodies have stopped working .The Researchers also said T Cell protection is a key feature of the adenovirus vaccines, like the oxford jab which is manufactured by Oxford Bio at their Oxford manufacturing facilities .
This is good news
BE HAPPY
DAVE

OXB is one one of my holdings ,I am aware of how this project went forward ,yes the government helped OXB with the cost of expanding our production facility in Oxford ,and fitted out the new OX box ,they all so helped with ratification of the manufacturing facilities ,but it still cost OXB a lot of money .That said ,the out come for OXB has been very positive as you can see from the share price .How ever Astra Zeneca have taken a bit of a hit ,as they partnered Oxford university in producing the Vaccine at no profit . If and when SAR finds a Manufacturing partner, and Agile is offered funding and phase acceleration, and they find a major Pharma to help them get the compounds through Pre - clinical/clinical trial stage. then things, could move forward quite quickly .How ever in order to get the pills on to the Pharmacy shelves ,it will still take at least a year or two to get authorisation from the FDA and or the E.U or N.I.C.E ,and even then, they have to get marketing authority from each country , which can take another 3 months .
What normally holds things up, is getting standard pharmacy products through trials , its totally different to how Vaccines are treated, For a start, Vaccines have a set trail of products that have all ready been approved ,all though in the MRNA vaccine, that was not the case and they did have to be approved separately, but in the other products such as the oxford one ,they took a SARs2 vaccine ,and then manipulated or enhanced it by adding part of the COVID 2 DNA ,each product then has to go through a one year trial ,unlike other products(3-5 years) even if they are accelerated Agile ,it would still take between 2 and 5 years to get clearance ,and that's assuming every thing goes' smoothly, and nothing goes' wrong on the way, to hold it up ,the chances of a drug getting through all its trails and on the shelfs, is less than 20% where as a vaccine can be done in 1year to 18 months , but again, only a few new vaccines make it, so lets hope SAR can get the funding, and Agile gets clearance .
BE HAPPY
DAVE

Hi Ahfam3 Since my last post we now know from the RNS, that the warrants have in fact been taken up and that is good , but what I was asking in my last post, is simple, can any body say what S.A.R will earn this year ? ,and what is the cash burn expected to be this year? the reason I ask is quite simple, as it is stated in last cash call, that net proceeds from the Subscription will be used to progress the Company's SDC-1801 and SDC-1802 TYK2/JAK1 inhibitor drug development programmes, as well as for working capital ,but how much was for working capital ,and how much went on R.D? and how much doe's it cost to run the company, and management each year . as you said in your own post the company said ,We are keen to progress this project to the next stage, and will now explore our options to find the best way to fund these next steps. I would point out that refers to the future not the past ..
BE HAPPY
DAVE

Looking through the accounts, I note, Sar have not produced any income to speak of since they started .So who pays for the staff , equipment etc ,who pays the BOD, they do get paid I suppose, who pays for transport and communications and how much cash burn is there each year ? any body know ?
People talk about Patents as if they are worth a fortune ,but that is not all ways the case ,as some patterns can be by passed, by big pharmers , GSK did it to VEC , it took 3 years of litigation in the USA courts ,and millions in cost's to defend that patent, could SAR do that ?
If a big pharma wants some thing, they normally use other means first to get it .Its a hard world out there for little start ups.
I'm not suggesting SAR is a little start up, but I think most people will understand what I am talking about ,especially if they have previously held Pharma share's. From what I have learnt over 25 years of investing in Bio shares , Nothing is binding until the deal is done, and proof of concept has been approved, and that phase one & two trials show their is no health problems or major side affects,. And that costs money, and lots of it ,even if most of your drugs have been licensed out or given to stakeholders to bring the product on , some body has to find the cash, but who?
BE HAPPY
DAVE

Hi Ahfram as you say SAR have some warrants to sell , how ever ,the stock price must stay above 7p for 5 consecutive days which probably means those who are buying will have done so by now . Im sorry to say I'm not sure what the cash burn here is per year ,but it must of increased quite considerably recently ,How ever I'm sure ,some one will be able to tell me what the burn rate is soon .My other point is, If you look further down this document it states
on 14 June 2021.
The net proceeds from the Subscription will be used to progress the Company's SDC-1801 and SDC-1802 TYK2/JAK1 inhibitor drug development programmes as well as for working capital purposes. As noted in the Company's Trading Update of 25 May 2021, the Company is targeting the completion of preclinical studies for SDC-1801 in Q3 2021, subject to successful progress. Clinical trial plans, including priority autoimmune indications and potential Covid-19 application, will also be developed in parallel, subject to additional funding being raised. note the last 6 words ,and, the word potential. so nothing is guaranteed yet .
BE HAPPY
DAVE

The obvious way to achieve a price of £3-£5 is to reduce the amount of shares out there, at the same time, the company should raise the 20m they will need to cover further trails .This procedure is done quite often with smaller companies ,for instance, OXB who also had over 3 billion shares in circulation and had problems with market instability ,so OXB did a consolidation, they also raised £20m at the same time ,yes it meant massif dilution ,but it did the trick . after the consolidation had taken place, each OXB share was worth £5 ,against a previous price ,that kept jumping between 8p and 12p, but now ,OXB shares are worth £13.50 each and are stable , so nothing is in possible in this game .
BE HAPPY
DAVE

Sorry Bobbler in my last post I stated in other words, the funding is not in place yet , hence, stage one trials wont start un till 2021, this should have un till 2022 and not 21,Im sorry about that ,but as I said I'm still holding , but I do expect strong swings to occur before then, if we don't get any info about funding soon ..
BE HAPPY
DAVE

Hi Bobbler
Your post is very interesting ,however, how do you explain the following sentence which clearly state's ,Subject to successful completion of the ongoing preclinical toxicology studies, requisite approvals and financing, the Company aims to commence Phase 1 clinical trials for SDC-1801 in early 2022. The timing and design of the clinical trials for Covid-19 applications will be determined following consultations with experts in the field.Note the point about Phase 1 clinical trials .Further more here is what Dr John Reader, CSO of Sareum, commented:

"The results from our Covid-19 research project are very encouraging and provide clear evidence of the potential of SDC-1801 to reduce the excessive inflammatory response seen in severe Covid-19. We are keen to progress this project to the next stage and will now explore our options to find the best way to fund these next steps. (note the sentene next step )This could include the UK government's AGILE clinical development platform, which was established to fund Phase 1 trials and fast-track the development of potentially ground-breaking Covid-19 treatments. These activities are expected to run in parallel with the broader SDC-1801 development plan targeting autoimmune diseases.
In other words the funding is not in place yet , hence, stage one trials wont start un till 2021,but I'm still holding , but I expect strong swings to occur before then, if we don't get any info soon ..
BE HAPPY
DAVE